I told a patient she had bladder cancer this morning, and she said to me that she would be clapping tonight ♥️🇬🇧😷♥️😷
El @DrFelixGuerrero presenta los resultados del ensayo HIVEC-HR, comunicado recientemente en #AUA20 @AmerUrological, en el webinar organizado por @CombatCancer #HIVEC #bladdercancer
➡ Más información: https://bit.ly/2A0qGwe
¡Sigue el webinar online 👉 https://bit.ly/3cV7HBV!
If you're free later today, 6pm Madrid time, please join us #HIVEC for presentation Q&A on HIVEC HR trial
https://hivec-hr.eventbrite.co.uk #HIVEC #AUA20
Please join Combat and Dr Guerrero-Ramos for a presentation of the HIVEC HR trial with live Q&A
https://hivec-hr.eventbrite.co.uk #HIVEC #AUA20
Please join Combat and Dr Guerrero-Ramos for a presentation of the HIVEC HR trial with live Q&A
Top Influencers of #AUA20: @CombatCancer @Urologia12 @AlejandroGoDiaz @GUOaeu @DrFelixGuerrero @InfoAeu More 📊
#AUA20
For more than a century, the AUA Annual Meeting has presented the most advanced science and technologies in urology, boasting a robust program unrival...
hcsm.io
#HIVEC #AUA20 @CombatCancer. Preliminary HIVEC HR trial data. Mean follow up 24 months, full abstract in The Journal of Urology https://bit.ly/2xF99Jh
We want to find out how Covid-19 is affecting bladder cancer patients & help the discussion on availability of cancer services for those who need treatment. Please take our quick survey for bladder cancer patients in the UK https://www.surveymonkey.co.uk/r/3Z6NMRV #bladdercancer #patients
Bladder cancer is a killer! Do not forget! If you decide to wait for a patient a TURB at least negative cytology!!! https://twitter.com/UroDocAsh/status/1255921703106076672
Delays in treatment have significant effect on survival for #bladdercancer patients, whether during #Covid19UK or during peacetime @pcvblack @JimCatto @Prof_Nick_James @PGrivasMDPhD @garysteinbergmd @bbmdmsk @MattGalsky @nnavai @drtanws @shilpaonc @BadarMian1 @BladderCancerUS https://twitter.com/tsoburol/status/1254659910371020802
Covid free Robotics. Staff and patients all swabbed and Covid free prior to surgery. Surrey and Sussex Cancer Hub getting back to work safely. Let’s get those cancer patients treated. @RoyalSurrey @GuildfordUrolo1 @_ProstateProjec @TUF_tweets
Congrats/ Enhorabuena @alarjosan for the fantastic article! @CombatCancer
Happy to publish our last study showing a less hospital stay and shorter time to chemo using laparoscopic approach for CRS-HIPEC in peritoneal carcinomatosis @HUReinaSofia @aecirujanos @SPeritoneum @operarelcancer @SurgEndosc @ESSOnews @me4_so @GECOP_ https://link.springer.com/article/10.1007/s00464-020-07572-x
@CombatCancer @GECOP_ @ESSOnews #combatcancer #combatcovid19
My colleagues @DukeGUCancer and I have been working hard during #COVID outbreak to develop a triaging system for urological cancers consistent with @AmCollSurgeons and @CMSGov guidance. I share our current paradigm here. Will update document as we learn from its implementation.
Combat’s team are here to support and offer assistance to all hospital’s treating HIVEC patients. Depending on the country we can offer support in person or via other methods of communication #HIVEC @CombatCancer #CombatCancer #CombatCoronavirus
Desde Combat Biosurgical mantenemos el servicio y la asistencia técnica de perfusion a los casos de cytoreducción con PRS+ HIPEC en España #combatcancer #COVID19 #CombatCoronavirus @CombatCancer @GECOP_ @ESSOnews #hipec #prs #YoMeQuedoEnCasa #StayHomeSaveLives
@alarjosan @aec @HUReinaSofia @CoronaVid19 @me4_so @SPeritoneum @AndaluciaJunta 👏
40 patients took part in the study, split into two groups – one which received the HIVEC™ treatment prior to a resection of the bladder, and another which received HIVEC after resection of the bladder.
97% of the patients were able to complete the full course of HIVEC treatments, and the majority of participants responded well to the treatment and show low rates of recurrence. Furthermore, the majority of the side-effects were low grade and had very little effect on the treatment plan.
Click Here to read the full article
Click Here to read the interview with the research author
